Trial Profile
An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Amlodipine/telmisartan (Primary) ; Antihypertensives
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
- 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.